Infectious Disease

Vonoprazane-based therapy shows promise for the eradication of H. pylori

November 24, 2021

Watch for 1 minute

Source / information

Published by:

Healio Logo - Gastroenterology

Source:

Chey WD et al. Vonoprazan dual and triple therapy for Helicobacter pylori eradication. Presented at: ACG Annual Scientific Meeting; 22.-27. October 2021; Las Vegas (hybrid meeting).

Disclosure:
Foster does not report any relevant financial information.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

In this video, C. Jonathan D. Foster, DO, FACOI, discussed a study on the use of vonoprazane-based therapies to treat Helicobacter pylori infection that was presented at the ACG’s annual scientific meeting.

“This study was very interesting and will bring a new perspective in the treatment of H. pylori to the market,” Foster, medical director of gastroenterology and advanced endoscopy at Jefferson Health New Jersey, told Healio.

In the study, researchers evaluated the efficacy and safety of dual and triple therapy with Vonoprazan (Takeda) versus triple therapy with lansoprazole in patients with treatment-naive H. pylori infection. The study met its primary endpoint, with results demonstrating the non-inferiority of dual and triple therapy of vonoprazan versus triple therapy of lansoprazole in patients with H. pylori who were not resistant to clarithromycin or amoxicillin.

In addition, the researchers found that both Vonoprazan therapies were superior to lansoprazole triple therapy in patients with clarithromycin-resistant strains as well as in the overall patient population. The treatment appeared to be safe even when compared to the triple lansoprazole therapy.

“This drug will really help us out in the treatment of H. pylori in the future,” said Foster. “This drug will benefit this patient population, especially those with clarithromycin-resistant strains, and will truly set a precedent in treating patients with H. pylori, thereby preventing gastric ulcers and malignancies.”

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

Take Homes in Infection

Take Homes in Infection

Related Articles